Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

NCT02416999 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Recurrent High-grade Glioma

Interventions

DRUG: Ultra-low dose Bevacizumab
DRUG: Temozolomide

Sponsor

Hebei Yanda Hospital

Collaborators

[object Object]